Design and validation of a thermoreversible material for percutaneous tissue hydrodissection

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 101, Issue 8, 2013, Pages 1400-1409

  Johnson, Alexander ^a,b   Sprangers, Anthony ^a   Cassidy, Patrick ^a   Heyrman, Sean ^a   Hinshaw, J Louis ^b   Lubner, Meghan ^b   Puccinelli, John ^a   Brace, Chris ^a,b  

^a Wisconsin Electric Machines and Power Electronics Consortium   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

ablation; D5W; hydrodissection; poloxamer 407; thermoreversible

Indexed keywords

ABLATION; COMPUTERIZED TOMOGRAPHY; GELATION; HISTOLOGY; SALINE WATER; VISCOSITY;

ELECTRICAL IMPEDANCE; ELECTRICAL PROTECTION; FEASIBLE ALTERNATIVES; GELATION TEMPERATURE; HYDRODISSECTION; POLOXAMER 407; THERMOREVERSIBLE; THERMOREVERSIBLE MATERIALS;

TISSUE;

BIOMATERIAL; GLUCOSE; POLOXAMER; SODIUM CHLORIDE; GEL; INORGANIC SALT; SURFACTANT;

ABLATION THERAPY; ANIMAL TISSUE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COW; EX VIVO STUDY; FEASIBILITY STUDY; GEL; GELATION; IMPEDANCE; NONHUMAN; PERCUTANEOUS TISSUE HYDRODISSECTION; SAFETY; ULTRASOUND; VALIDATION PROCESS; VISCOSITY; ANIMAL; CHEMISTRY; DISSECTION; DRUG EFFECTS; ECHOGRAPHY; EQUIPMENT DESIGN; HUMAN; MATERIALS TESTING; MICROWAVE RADIATION; PERITONEUM; PHASE TRANSITION; PROCEDURES; RADIOFREQUENCY RADIATION; RAT; TEMPERATURE;

ANIMALS; DISSECTION; ELECTRIC IMPEDANCE; EQUIPMENT DESIGN; GELS; GLUCOSE; HUMANS; MATERIALS TESTING; MICROWAVES; PERITONEUM; PHASE TRANSITION; POLOXAMER; RADIO WAVES; RATS; SALTS; SURFACE-ACTIVE AGENTS; TEMPERATURE; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY; VISCOSITY;

EID: 84886475425     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.32959     Document Type: Article

References (43)

1. Permpongkosol S, Link RE, Kavoussi LR, Solomon SB,. Temperature measurements of the low-attenuation radiographic ice ball during ct-guided renal cryoablation. Cardiovasc Interv Radiol 2008; 31: 116-121.
2. Yoon J, Cho J, Kim N, Kim DD, Lee E, Cheon C, Kwon Y,. High frequency microwave ablation method for enhanced cancer treatment with minimized collateral damage. Int J Cancer 2011; 129: 1970-1978.
3. Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, Paties C, Silverman D, Buscarini L,. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am J Roentgenol 1996; 167: 759-768.
4. Paganini AM, Rotundo A, Barchetti L, Lezoche E,. Cryosurgical ablation of hepatic colorectal metastases. Surg Oncol 2007; 16: 137-140.
5. Lubner MG, Brace CL, Hinshaw JL, Lee FT,. Microwave tumor ablation: Mechanism of action, clinical results, and devices. J Vasc Intervent Radiol 2010; 21: S192-S203.
6. Hinshaw JL, Laeseke PF, Winter III TC, Kliewer MA, Fine JP, Lee FT Jr,. Radiofrequency ablation of peripheral liver tumors: Intraperitoneal 5% dextrose in water decreases postprocedural pain. Am J Roentgenol 2006; 186 (5 Suppl): S306.
7. Brace CL, Laeseke PF, Prasad V, Lee FT,. Electrical isolation during radiofrequency ablation: 5% dextrose in water provides better protection than saline. Eng Med Biol Soc 2002; 28: 5021-5024.
8. Callstrom MR, Kurup AN,. Percutaneous ablation for bone and soft tissue metastases-Why cryoablation? Skelet Radiol 2009; 38: 835-839.
9. Callstrom MR, Charboneau JW,. Technologies for ablation of hepatocellular carcinoma. Adolesc Med Clin 2008; 134: 1831-1835.
10. Mertyna P, Goldberg W, Yang W, Goldberg SN,. Thermal ablation: A comparison of thermal dose required for radiofrequency-, microwave-, and laser-induced coagulation in an ex vivo bovine liver model. Acad Radiol 2009; 16: 1539-1548.
11. Al-Sakere B, André F, Bernat C, Connault E, Opolon P, Davalos RV, Rubinsky B, Mir LM,. Tumor ablation with irreversible electroporation. PLoS One 2007; 2: e1135.
12. Dodd GD, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y, Gillams AR, Karahan OI, Rhim H,. Minimally invasive treatment of malignant hepatic tumors: At the threshold of a major breakthrough. Radiographics 2000; 20: 9.
13. Kuang M, Lu MD, Xie XY, Xu HX, Mo LQ, Liu GJ, Xu ZF, Zheng YL, Liang JY,. Liver cancer: Increased microwave delivery to ablation zone with cooled-shaft antenna-Experimental and clinical studies. Radiology 2007; 242: 914-924.
14. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S,. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2007; 47: 82-89.
15. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR,. Renal cell carcinoma: Clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology 2003; 226: 417-424.
16. Lee SJ, Choyke LT, Locklin JK, Wood BJ,. Use of hydrodissection to prevent nerve and muscular damage during radiofrequency ablation of kidney tumors. J Vasc Intervent Radiol 2006; 17: 1967-1969.
17. Laeseke PF, Sampson LA, Brace CL, Winter III TC, Fine JP, Lee FT Jr,. Unintended thermal injuries from radiofrequency ablation: Protection with 5% dextrose in water. Am J Roentgenol 2006; 186 (5 Suppl): S249.
18. Kim Y, Rhim H, Choi D, Lim HK,. Does artificial ascites induce the heat-sink phenomenon during percutaneous radiofrequency ablation of the hepatic subcapsular area? An in vivo experimental study using a rabbit model. Korean J Radiol 2009; 10: 43-50.
19. Chen EA, Neeman Z, Lee FT, Kam A, Wood B,. Thermal protection with 5% dextrose solution blanket during radiofrequency ablation. Cardiovasc Intervent Radiol 2006; 29: 1093-1096.
20. Webb H, Lubner MG, Hinshaw JL,. Thermal ablation. Semin Roentgenol 2011; 46: 133-141.
21. Rhim H, Lim HK, Kim Y-S, Choi D,. Percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma in the hepatic dome: Initial experience. Am J Roentgenol 2008; 190: 91-98.
22. Kondo Y, Yoshida H, Shiina S, Tateishi R, Teratani T, Omata M,. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract. Br J Surg 2006; 93: 1277-1282.
23. Bodily KD, Atwell TD, Mandrekar JN, Farrell MA, Callstrom MR, Schmit GD, Charboneau JW,. Hydrodisplacement in the percutaneous cryoablation of 50 renal tumors. Am J Roentgenol 2010; 194: 779-783.
24. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC,. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 2006; 23: 2709-2728.
25. Ricci E, Lunardi L, Nanclares D, Marchetti J,. Sustained release of lidocaine from Poloxamer 407 gels. Int J Pharm 2005; 288: 235-244.
26. Misirlis D,. Development of a Novel Drug Delivery System Based on Polymeric, Thermoresponsive, Hydrogel Nanoparticles. De Lausanne: École Polytechnique Fédérale; 2005.
27. Yu L, Ding J,. Injectable hydrogels as unique biomedical materials. Chem Soc Rev 2008; 37: 1473-1481.
28. Singh-Joy S, McLain V,. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol 2008; 27: 93.
29. Ricci E, Bentley M, Farah M, Bretas R, Marchetti J,. Rheological characterization of Poloxamer 407 lidocaine hydrochloride gels. Eur J Pharm Sci 2002; 17: 161-167.
30. Gilbert JC, Richardson JL, Davies MC, Palin KJ, Hadgraft J,. The effect of solutes and polymers on the gelation properties of pluronic F-127 solutions for controlled drug delivery. J Controlled Release 1987; 5: 113-118.
31. Schmolka I,. Artificial skin I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res 1972; 6: 571-582.
32. Dewhirst MW, Viglianti BL, Lora-Michiels M, Hanson, M, Hoopes PJ,. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia 2003; 19: 267-294.
33. Storm FK, Harrison WH, Elliott RS, Morton DL,. Normal tissue and solid tumor effects of hyperthermia in animal models and clinical trials. Cancer Res 1979; 39 (6 Part 2): 2245-2251.
34. Sapareto SA, Dewey WC,. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 1984; 10: 787-800.
35. Nikfarjam M, Muralidharan V, Christophi C,. Mechanisms of focal heat destruction of liver tumors. J Surg Res 2005; 127: 208-223.
36. Pec E, Wout Z, Johnston T,. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. J Pharm Sci 1992; 81: 626-630.
37. Jeong B, Kim SW, Bae YH,. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev 2002; 54: 37-51.
38. Ruel-Gariépy E, Leroux J-C,. In situ-forming hydrogels-Review of temperature-sensitive systems. Eur J Pharm Biopharm 2004; 58: 409-426.
39. Johnston TP, Miller SC,. Toxicological evaluation of poloxamer vehicles for intramuscular use. PDA J Pharm Sci Technol 1985; 39: 83-89.
40. Johnston T, Beris H, Wout Z, Kennedy J,. Effects on splenic, hepatic, hematological, and growth parameters following high-dose poloxamer 407 administration to rats. Int J Pharm 1993; 100: 279-284.
41. BASF. Lutrol F 127. Material Safety Data Sheet 2010; 1: 1-6.
42. Cabana A, Ait-Kadi A, Juhasz J,. Study of the gelation process of polyethylene oxidea-polypropylene oxideb-polyethylene oxidea copolymer (Poloxamer 407) aqueous solutions. J Colloid Interface Sci 1997; 190: 307.
43. Ur-Rehman T,. Controlled Release Gel Formulations and Preclinical Screening of Drug Candidates. Umeå University; 2011; 1: 61.